Biopharmaceutical company Silo Pharma has carried out an animal study investigating the topical administration of ketamine for pain reduction.
Silo Pharma’s topically administered ketamine reached a positive endpoint in an animal study, says the company.
The formulation reduced mechanical allodynia – pain from stimuli that would not normally produce pain – and hyperalgesia – increased sensitivity, or heightened response to pain – at both the pre-and post-dosing time points.
Mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.
Eric Weisblum, CEO of Silo Pharma, commented: “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction.
“This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”
Silo Pharma is focusing on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. The company recently announced that it has entered into a commercial evaluation license agreement with the University of Maryland Baltimore for next-gen liposomes therapeutics to target multiple diseases, including autoimmune disorders.
[activecampaign form=52]
